HbA1c and type 2 diabetes are closely linked — this single blood test is the cornerstone of both diagnosing and monitoring the condition across the UK. By measuring glycated haemoglobin, HbA1c reflects your average blood glucose over the preceding two to three months, offering a far more reliable picture of glucose control than a one-off reading. Whether you have recently been diagnosed, are reviewing your treatment plan, or simply want to understand your results better, this guide explains what your HbA1c means, what targets to aim for, and the lifestyle and medical options available to help you manage your blood sugar effectively.

What Is HbA1c and Why It Matters in Type 2 Diabetes

HbA1c measures glycated haemoglobin to reflect average blood glucose over two to three months and is the cornerstone diagnostic and monitoring tool for type 2 diabetes under NICE NG28.

HbA1c, or glycated haemoglobin, is a blood test that reflects your average blood glucose levels over the preceding two to three months. When glucose circulates in the bloodstream, it binds to haemoglobin — the protein found inside red blood cells — forming glycated haemoglobin. Because red blood cells have a lifespan of roughly 90 days, the HbA1c result provides a reliable snapshot of longer-term glucose control, rather than a single moment in time.

In the context of type 2 diabetes, HbA1c is considered the cornerstone diagnostic and monitoring tool. According to NICE guidelines (NG28), a result of 48 mmol/mol (6.5%) or above on two separate occasions is used to confirm a diagnosis of type 2 diabetes in adults without symptoms. For those already diagnosed, regular HbA1c testing — typically every 3–6 months until stable, then every 6 months — helps clinicians and patients assess how well blood glucose is being managed.

Important limitations of HbA1c for diagnosis HbA1c is not appropriate for diagnosing diabetes in all situations. NICE advises that plasma glucose criteria should be used instead in the following circumstances:

• Pregnancy (including gestational diabetes)

• Children and young people

• Suspected type 1 diabetes

• People with symptoms present for fewer than two months, or during acute illness

• Conditions that affect red blood cell turnover or haemoglobin structure (such as haemolytic anaemia or haemoglobin variants)

In these situations, fasting plasma glucose or an oral glucose tolerance test is more appropriate. Your GP or diabetes team will advise on the correct test for your circumstances.

The importance of monitoring HbA1c cannot be overstated. Persistently elevated levels are strongly associated with an increased risk of serious long-term complications, including:

• Cardiovascular disease (heart attack and stroke)

• Diabetic nephropathy (kidney damage)

• Diabetic retinopathy (sight-threatening eye disease)

• Peripheral neuropathy (nerve damage, particularly in the feet)

By keeping HbA1c within a recommended target range, individuals with type 2 diabetes can significantly reduce their risk of these complications. The test is straightforward, requiring only a small blood sample, and is routinely available through NHS GP practices and diabetes clinics.

Key references: NICE NG28 (Type 2 diabetes in adults: management); NHS HbA1c test patient information.

Understanding Your HbA1c Target Range

NICE recommends 48 mmol/mol for most adults on lifestyle measures or metformin, and 53 mmol/mol for those on hypoglycaemia-risk medications; targets are individualised based on health, frailty, and treatment regimen.

HbA1c targets in type 2 diabetes are not one-size-fits-all. NICE guidance (NG28) recommends an individualised approach, taking into account a person's overall health, treatment regimen, risk of hypoglycaemia, and personal preferences. Shared decision-making between the person and their care team is central to agreeing a target, and the rationale for any relaxed or tightened goal should be documented.

For most adults with type 2 diabetes managed through lifestyle changes or a single non-hypoglycaemic medication (such as metformin), NICE recommends an HbA1c target of 48 mmol/mol (6.5%). If a person is taking one or more medications that carry a risk of hypoglycaemia — such as sulphonylureas or insulin — the target is slightly relaxed to 53 mmol/mol (7.0%) to reduce the risk of dangerously low blood sugar episodes.

It is worth understanding what these numbers mean in practice:

• Below 48 mmol/mol: Generally considered within the normal range for people without diabetes

• 48–53 mmol/mol: The typical target zone for many people with well-managed type 2 diabetes

• Above 58 mmol/mol: NICE advises considering intensification of treatment when HbA1c reaches or exceeds 58 mmol/mol despite the current regimen

• Above 75 mmol/mol: Associated with a substantially elevated risk of diabetes-related complications; this level warrants prompt clinical review and, in most cases, urgent treatment intensification

For older adults, those with frailty, multiple long-term conditions, or a limited life expectancy, clinicians may agree a less stringent target to prioritise quality of life and avoid the harms of over-treatment. Conversely, younger individuals or those newly diagnosed may be encouraged to aim for tighter control. Always discuss your personal target with your GP or diabetes care team, as the right goal for you depends on your full clinical picture.

Key references: NICE NG28 (HbA1c targets and intensification thresholds).

Factors That Can Affect Your HbA1c Result

Conditions altering red blood cell lifespan — such as haemolytic anaemia, iron deficiency, or advanced CKD — can produce falsely low or high HbA1c readings, requiring alternative glucose assessments.

While HbA1c is a highly useful measure, certain medical conditions and physiological factors can influence the result, sometimes giving a falsely high or falsely low reading that does not accurately reflect true glucose control.

Conditions that may cause a falsely low HbA1c include:

• Haemolytic anaemia (where red blood cells are destroyed more rapidly, shortening their lifespan and reducing glycation time)

• Recent significant blood loss or blood transfusion

• Certain haemoglobin variants (e.g., sickle cell trait or haemoglobin C disease) — though the direction and magnitude of interference depends on the specific assay used; your laboratory can advise whether results are reliable for your haemoglobin variant

• Chronic kidney disease (CKD): advanced CKD and the use of erythropoietin (EPO) therapy can shorten red blood cell survival, which may lower HbA1c relative to true glucose levels; the effect varies with the degree of anaemia and the assay method used, so HbA1c results in CKD should be interpreted alongside glucose profiles

Conditions that may cause a falsely high HbA1c include:

• Iron deficiency anaemia (before treatment begins, due to prolonged red blood cell survival)

• Vitamin B12 or folate deficiency

• Splenectomy (removal of the spleen), which prolongs red blood cell lifespan

A note on iron supplementation: Starting iron therapy for iron deficiency anaemia can transiently affect HbA1c results as red blood cell turnover normalises; results should be interpreted with caution during this period.

In situations where HbA1c is unreliable, alternative measures of glucose control may be more appropriate. Fructosamine or glycated albumin reflect average glucose over approximately two to three weeks, but are affected by conditions that alter protein levels (such as nephrotic syndrome or liver disease). Continuous glucose monitoring (CGM) may be considered for people with type 2 diabetes who use insulin and meet specific NICE criteria; your diabetes team can advise on eligibility.

HbA1c should not be used for diagnosis in pregnancy or where red blood cell turnover is significantly altered — plasma glucose-based tests are preferred in these circumstances (see NICE NG28).

It is also worth noting that HbA1c does not capture glucose variability — the fluctuations between high and low blood sugar levels throughout the day. Two individuals can have the same HbA1c result yet experience very different patterns of glucose control. This is one reason why HbA1c is increasingly used alongside other monitoring tools, particularly for people on insulin therapy.

Ethnicity may also play a modest role; some studies suggest that people of African-Caribbean or South Asian heritage may have slightly different HbA1c values relative to their actual glucose levels, though no official clinical adjustment is recommended in current UK guidelines.

Key references: NICE NG28 (diagnosis exceptions and limitations); RCPath/UK laboratory guidance on HbA1c interferences; BSH guidance on haemoglobinopathies and glycaemic assessment; NHS HbA1c test patient information.

How to Lower HbA1c Through Lifestyle and Treatment

Lowering HbA1c combines dietary changes, physical activity, and weight management as first-line measures, with metformin and additional agents such as SGLT-2 inhibitors or GLP-1 receptor agonists added when targets are not met.

Reducing HbA1c in type 2 diabetes typically involves a combination of sustained lifestyle changes and, where necessary, pharmacological treatment. NICE guidance (NG28) emphasises that structured lifestyle intervention should be the foundation of diabetes management, with medication introduced or intensified when targets are not met.

Dietary changes are among the most impactful interventions. Evidence supports:

• Reducing intake of refined carbohydrates and added sugars

• Following a Mediterranean-style, low-glycaemic index, or low-carbohydrate diet

• Increasing fibre intake through vegetables, pulses, and wholegrains

• Avoiding sugary drinks and ultra-processed foods

A reduction in body weight of even 5–10% has been shown to produce clinically meaningful improvements in HbA1c. For some people with recently diagnosed type 2 diabetes, substantial weight loss (typically 15 kg or more through a structured programme) may achieve remission of diabetes.

Weight management and metabolic surgery NICE guidance (CG189) recommends referral to a tiered weight management service for eligible individuals. Metabolic (bariatric) surgery may be considered for adults with a BMI of 40 kg/m² or above, or 35–39.9 kg/m² with a significant obesity-related condition such as type 2 diabetes. For people with recent-onset type 2 diabetes, surgery may be considered at a BMI of 30–34.9 kg/m². Eligibility depends on individual clinical assessment and should be discussed with your care team.

Physical activity also plays a significant role. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training improve insulin sensitivity and help lower blood glucose. In line with UK Chief Medical Officers' guidelines, adults with type 2 diabetes are advised to aim for at least 150 minutes of moderate-intensity aerobic activity per week, alongside muscle-strengthening activities on at least two days per week.

Pharmacological treatment When lifestyle measures alone are insufficient, medication is introduced. Metformin remains the first-line pharmacological treatment for most people with type 2 diabetes, provided renal function is adequate (refer to the SmPC for eGFR thresholds). If HbA1c remains above target, additional agents may be added. NICE NG28 advises that the choice of second-line therapy should be guided by individual clinical circumstances:

• SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin): NICE recommends prioritising these agents — often alongside or instead of metformin depending on tolerability and renal function — for adults with type 2 diabetes who have established cardiovascular disease, high cardiovascular risk, heart failure, or chronic kidney disease, given their additional cardio-renal protective benefits. Prescribing should be in accordance with the relevant SmPC and eGFR thresholds.

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide): support weight loss alongside glucose lowering and are particularly beneficial for people with obesity or cardiovascular disease

• Pioglitazone (a thiazolidinedione): may be appropriate for some individuals; it should be avoided in people with heart failure or a high risk of fragility fractures

• DPP-4 inhibitors, sulphonylureas, or insulin, depending on individual clinical need and tolerability

Shared decision-making is central to choosing the right medication. Your GP or diabetes team will consider your full clinical picture, including kidney function, cardiovascular risk, weight, and personal preferences.

If your HbA1c remains persistently elevated despite treatment, or if you experience symptoms such as excessive thirst, frequent urination, or unexplained weight loss, contact your GP promptly. Regular review with your diabetes care team is essential to ensure your management plan remains appropriate and effective.

Key references: NICE NG28 (treatment choices, SGLT-2 indications, metformin/eGFR considerations); NICE CG189 (obesity: identification, assessment and management); UK Chief Medical Officers' Physical Activity Guidelines; NHS/Diabetes UK dietary guidance for type 2 diabetes; MHRA/EMC SmPCs for metformin, SGLT-2 inhibitors, GLP-1 receptor agonists, and pioglitazone.

Frequently Asked Questions